$23.61
7.03% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US15117B1035
Symbol
CLDX

Celldex Therapeutics, Inc. Stock price

$23.61
+1.81 8.30% 1M
+4.26 22.02% 6M
-1.66 6.57% YTD
-17.89 43.11% 1Y
-6.43 21.40% 3Y
+12.24 107.65% 5Y
-185.34 88.70% 10Y
+2.61 12.43% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+1.55 7.03%
ISIN
US15117B1035
Symbol
CLDX
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$834.6m
Net debt
positive
Cash
$630.3m
Shares outstanding
66.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
253.0 | 373.2
EV/Sales
144.1 | 212.6
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
94.3%
Return on Equity
-21.1%
ROCE
-35.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$5.8m | $3.9m
EBITDA
$-231.4m | $-254.8m
EBIT
$-234.7m | $-258.1m
Net Income
$-199.6m | $-235.4m
Free Cash Flow
$-188.5m
Growth (TTM | estimate)
Revenue
-30.3% | -44.1%
EBITDA
-34.0% | -32.8%
EBIT
-33.5% | -32.3%
Net Income
-32.9% | -49.1%
Free Cash Flow
-53.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,995.9% | -6,492.2%
EBIT
-4,053.7%
Net
-3,446.9% | -5,996.2%
Free Cash Flow
-3,254.8%
More
EPS
$-3.0
FCF per Share
$-2.8
Short interest
13.0%
Employees
186
Rev per Employee
$40.0k
Show more

Is Celldex Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Celldex Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Celldex Therapeutics, Inc. forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a Celldex Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Celldex Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5.79 5.79
30% 30%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 42 42
18% 18%
717%
- Research and Development Expense 199 199
46% 46%
3,437%
-231 -231
34% 34%
-3,997%
- Depreciation and Amortization 3.35 3.35
8% 8%
58%
EBIT (Operating Income) EBIT -235 -235
34% 34%
-4,054%
Net Profit -200 -200
33% 33%
-3,447%

In millions USD.

Don't miss a Thing! We will send you all news about Celldex Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celldex Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
13 days ago
Celldex Therapeutics, Inc.'s barzolvolimab failed to improve symptoms in eosinophilic esophagitis, but this setback doesn't impact its promising ongoing urticaria programs. Phase 3 trials for chronic spontaneous urticaria are underway, with additional studies for chronic inducible urticaria set to begin soon in 2nd half of 2025. The global urticaria market size is projected to reach $11.4 billi...
Neutral
GlobeNewsWire
15 days ago
HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. Identifying the key drivers of EoE has challenged the field and research has suggested that mast cells could play an important role in...
Neutral
GlobeNewsWire
27 days ago
HAMPTON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2025 and provided a corporate update.
More Celldex Therapeutics, Inc. News

Company Profile

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Head office United States
CEO Anthony Marucci
Employees 186
Founded 1983
Website celldex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today